News & Events about Scholar Rock Holding Corp.
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) major shareholder Public Equities L.P. Invus bought 48,774 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The shares were bought at an average cost of $9.33 per share, for a total transaction of $...
Scholar Rock Holding Co. (NASDAQ:SRRK Get Rating) major shareholder Public Equities L.P. Invus bought 48,774 shares of the companys stock in a transaction that occurred on Thursday, January 5th. The shares were bought at an average cost of $9.33 per share, for a total transaction of $455,061.42. ...
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January...
Business Wire
2 months ago
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced early data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of...
Business Wire
2 months ago
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer. Dr. Marantz is an...